CN112313235A - 作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物 - Google Patents

作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物 Download PDF

Info

Publication number
CN112313235A
CN112313235A CN201980039582.5A CN201980039582A CN112313235A CN 112313235 A CN112313235 A CN 112313235A CN 201980039582 A CN201980039582 A CN 201980039582A CN 112313235 A CN112313235 A CN 112313235A
Authority
CN
China
Prior art keywords
absent
phenyl
compound
substituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980039582.5A
Other languages
English (en)
Chinese (zh)
Inventor
南基然
金在昇
田義珍
兪東勳
徐武永
朴桐湜
J.艾克霍夫
G·齐施因斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center GmbH
Qurient Co Ltd
Original Assignee
Lead Discovery Center GmbH
Qurient Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center GmbH, Qurient Co Ltd filed Critical Lead Discovery Center GmbH
Publication of CN112313235A publication Critical patent/CN112313235A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980039582.5A 2018-04-11 2019-04-11 作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物 Pending CN112313235A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656070P 2018-04-11 2018-04-11
US62/656,070 2018-04-11
PCT/EP2019/059302 WO2019197549A1 (en) 2018-04-11 2019-04-11 Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase

Publications (1)

Publication Number Publication Date
CN112313235A true CN112313235A (zh) 2021-02-02

Family

ID=66334385

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980039582.5A Pending CN112313235A (zh) 2018-04-11 2019-04-11 作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物

Country Status (14)

Country Link
US (1) US11945822B2 (enExample)
EP (1) EP3774810A1 (enExample)
JP (2) JP7772501B2 (enExample)
KR (1) KR102966455B1 (enExample)
CN (1) CN112313235A (enExample)
AU (1) AU2019250507B2 (enExample)
BR (1) BR112020020768A2 (enExample)
CA (1) CA3095880A1 (enExample)
IL (1) IL277770B2 (enExample)
MX (1) MX2020010675A (enExample)
MY (1) MY199647A (enExample)
PH (1) PH12020551639A1 (enExample)
SG (1) SG11202009724YA (enExample)
WO (1) WO2019197549A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114195710A (zh) * 2021-12-20 2022-03-18 上海彩迩文生化科技有限公司 一种喹啉类胺甲基化合物的制备方法
CN117756747A (zh) * 2023-12-21 2024-03-26 济宁医学院 一种n-苯基含氮多元环季铵盐类化合物的制备方法
WO2024175024A1 (zh) * 2023-02-21 2024-08-29 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220144841A1 (en) * 2019-03-13 2022-05-12 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
US20230115907A1 (en) 2019-12-20 2023-04-13 Evopoint Biosciences Co., Ltd. Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof
CA3174507A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
CN112079781B (zh) * 2020-09-30 2022-11-22 苏州康润医药有限公司 5-溴-1-甲基-1h-吡唑-3-胺的合成方法
EP4255909A1 (en) 2020-12-02 2023-10-11 Qurient Co. Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2024151112A1 (ko) * 2023-01-11 2024-07-18 주식회사 티움바이오 사이클린 의존성 키나아제 9 저해제로서의 피라졸로피리미딘 유도체
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
WO2025024726A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinase

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735614A (zh) * 2002-09-04 2006-02-15 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
CN1922185A (zh) * 2004-02-25 2007-02-28 先灵公司 作为激酶抑制剂的吡唑并三嗪类化合物
CN101321757A (zh) * 2005-10-06 2008-12-10 先灵公司 用于治疗癌症的依赖细胞周期蛋白的激酶抑制剂吡唑并嘧啶化合物
JP2009007342A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
CN101541804A (zh) * 2006-10-04 2009-09-23 先灵公司 作为细胞周期素依赖性激酶抑制剂的吡唑并嘧啶
WO2013128029A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
CN104350054A (zh) * 2012-03-01 2015-02-11 利德探索中心有限公司 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并-三嗪衍生物
CN107530329A (zh) * 2015-03-09 2018-01-02 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP2010529140A (ja) * 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3805218A1 (en) 2014-04-05 2021-04-14 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2019144149A2 (en) * 2018-01-22 2019-07-25 Fred Hutchinson Cancer Research Center Treatment methods for pancreatic tumors associated with the worst prognosis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735614A (zh) * 2002-09-04 2006-02-15 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
CN1880317A (zh) * 2002-09-04 2006-12-20 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
CN1922185A (zh) * 2004-02-25 2007-02-28 先灵公司 作为激酶抑制剂的吡唑并三嗪类化合物
CN101321757A (zh) * 2005-10-06 2008-12-10 先灵公司 用于治疗癌症的依赖细胞周期蛋白的激酶抑制剂吡唑并嘧啶化合物
CN101541804A (zh) * 2006-10-04 2009-09-23 先灵公司 作为细胞周期素依赖性激酶抑制剂的吡唑并嘧啶
JP2009007342A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
WO2013128029A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
CN104350054A (zh) * 2012-03-01 2015-02-11 利德探索中心有限公司 作为选择性细胞周期蛋白依赖性激酶抑制剂的吡唑并-三嗪衍生物
CN107530329A (zh) * 2015-03-09 2018-01-02 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1,5‑a][1,3,5]三嗪和吡唑并[1,5‑a]嘧啶衍生物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114195710A (zh) * 2021-12-20 2022-03-18 上海彩迩文生化科技有限公司 一种喹啉类胺甲基化合物的制备方法
WO2024175024A1 (zh) * 2023-02-21 2024-08-29 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
CN117756747A (zh) * 2023-12-21 2024-03-26 济宁医学院 一种n-苯基含氮多元环季铵盐类化合物的制备方法

Also Published As

Publication number Publication date
NZ768649A (en) 2024-10-25
WO2019197549A1 (en) 2019-10-17
AU2019250507B2 (en) 2023-09-28
IL277770B2 (en) 2024-01-01
AU2019250507A1 (en) 2020-10-22
MX2020010675A (es) 2020-10-28
KR20200141487A (ko) 2020-12-18
PH12020551639A1 (en) 2021-07-05
KR102966455B1 (ko) 2026-05-15
MY199647A (en) 2023-11-14
JP7772501B2 (ja) 2025-11-18
SG11202009724YA (en) 2020-10-29
IL277770B1 (en) 2023-09-01
US20210147427A1 (en) 2021-05-20
US11945822B2 (en) 2024-04-02
JP2023138858A (ja) 2023-10-02
JP2021521120A (ja) 2021-08-26
IL277770A (en) 2020-11-30
BR112020020768A2 (pt) 2021-01-19
CA3095880A1 (en) 2019-10-17
EP3774810A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
KR102966455B1 (ko) 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체
JP6959299B2 (ja) 新規化合物
JP7406501B2 (ja) 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
CN101827848B (zh) 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
CN108026045B (zh) 用作RORγ调节剂的经过取代的四氢喹啉酮化合物
TWI694826B (zh) 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
CN113061132B (zh) 一类稠环内酰胺类化合物、制备方法和用途
ES2954152T3 (es) Moduladores del receptor de piperidina CXCR7
AU2013227024B2 (en) Novel piperidine compound or salt thereof
CN111491918A (zh) 芳基和杂芳基取代的吲哚化合物
JP6733050B2 (ja) Ｒｉｐｋ２の阻害剤としてのヘテロアリールカルボキサミド化合物
JP2020533376A (ja) ピラゾロピリミジノン化合物およびその使用
AU2007287319A1 (en) Pyrimidone compounds as GSK-3 inhibitors
TW201706266A (zh) Ｃｃｒ２調節劑
US20190263828A1 (en) Heteroaromatic compounds as vanin inhibitors
JP7597709B2 (ja) 置換インドールおよびインダゾール化合物
CN110114357B (zh) 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物
HK1206739A1 (en) 3,4-disubstituted 1 h-pyrazole and 4,5-disubstituted thiazole inhibitors of syk
US20240343732A1 (en) Compounds for degradation of cyclin-dependent kinase 7(cdk7)
CN111205281B (zh) 杂环化合物及其用途
RU2809779C2 (ru) Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
KR20220136395A (ko) Irak4 억제제로서 유용한 트리시클릭 헤테로아릴 화합물
JP2022541819A (ja) Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
WO2024140319A1 (zh) 一种嘧啶类化合物及其制备方法和医药用途
AU2021212085A1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination